My lab focuses on two core research areas: anti-tumor drug discovery and tumor metabolism-immune crosstalk. We have established multiple cell- and molecular-based high-throughput screening platforms, successfully identifying and validating several small-molecule compounds that reverse tumor drug resistance. In the field of tumor metabolism and immune response, our work has revealed the critical roles of key post-translational modifications, including O-glycosylation and lactylation, in regulating tumor metabolic reprogramming and immune evasion. We also clarified the mechanistic link between DNA damage repair and innate immunity, providing new insights into cancer progression and therapeutic intervention.

Main research directions :

Tumor Metabolism and Epigenetics

DNA Damage Repair and Host Immune Response

Representative academic achievements：

Yi Zhang, et al. O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer. Nature Communication, 2024 Jul 3;15(1):5597. (First Author, IF: 15.7)

SY Zhou, Yi Zhang*,et al. And-1 coordinates with polymerase δ to regulate nucleotide excision repair and UVB-induced skin tumorigenesis. Nature Communications, 2025 Oct 21;16(1):9313. (Co-First Author and Co-Corresponding Author, IF: 15.7)

SY Zhou, Yi Zhang*, et al. Stabilization of RUNX1 Induced by O-GlcNAcylation Promotes PDGF-BB-Mediated Resistance to CDK4/6 Inhibitors in Breast Cancer. Cancer Research, 2025 May 2;85(9):1708-1724. (Co-First Author and Co-Corresponding Author, IF: 16.6)

Yi Zhang,et al. And-1 Coordinates with the FANCM Complex to Regulate Fanconi Anemia Signaling and Cisplatin Resistance. Cancer Research, 2022, 82 (18): 3249–3262. (First Author, IF: 16.6)

Yi Zhang,et al. Identification of potent SENP1 inhibitors that inactivate SENP1/JAK2/STAT signaling pathway and overcome platinum drug resistance in ovarian cancer. Clinical and Translational Medicine, 2021 Dec; 11(12): e649. (First Author, IF: 6.8)

E-mail：zhangyi25@jnu.edu.cn